Physician profile
Terri A Sullivan
NPI 1225052160
$2,841.74
in general payments reported to CMS, 2019-2025
27 companies · $479 in 2025
The $479 reported for 2025 was more than what 80% of Occupational Health (Nurse Practitioner) providers received nationally (typical 2025 total: $136).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $684 · 2022: $568 · 2023: $522 · 2024: $589 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,589.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $503.46 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $229.88 | 2021-2023 | |
| Pfizer INC. | $227.93 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $197.63 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.54 | 2021-2024 | Stiolto Respimat, Spiriva Respimat, Jardiance |
| Lilly USA, LLC | $188.37 | 2021-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $186.15 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Ardelyx, INC. | $147.05 | 2023-2024 | Ibsrela |
| Exact Sciences Corporation | $127.56 | 2023-2024 | Cologuard Collection Kit |
| Therapeuticsmd, INC. | $78.77 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $77.02 | 2025 | Airsupra |
| Glaxosmithkline, LLC. | $73.27 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.09 | 2021-2023 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $67.46 | 2021 | |
| Aimmune Therapeutics, INC. | $61.54 | 2024-2025 | Zenpep, Vowst |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $60.71 | 2024 | Rexulti, Abilify Maintena |
| Exeltis, USA INC. | $59.61 | 2022-2023 | Slynd |
| Paratek Pharmaceuticals, INC. | $58.73 | 2024-2025 | Nuzyra |
| Seqirus USA INC | $40.86 | 2024-2025 | Fluad, Flucelvax |
| Phathom Pharmaceuticals, INC. | $32.00 | 2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $32.00 | 2021 | |
| Hologic Sales and Service, LLC | $27.60 | 2025 | Aptima, Thinprep 2000 Processor |
| Medtronic, INC. | $24.86 | 2023 | Venaseal |
| Gilead Sciences, INC. | $20.19 | 2022 | |
| Mylan Specialty L.P. | $19.41 | 2021 | |
| Merck Sharp & Dohme LLC | $17.16 | 2021 | |
| Lucid Diagnostics INC. | $15.89 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terri Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.